Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz

In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
More news in Industry
Cyient Semiconductors secures $10 million strategic investment from GlobalFoundries
Three bank unions call for strike on December 3
ACME seals $3.6-billion deal for Odisha green ammonia project